pcn poster

Posters

Development of JZP-258, a Low-Sodium Formulation of Oxybate for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

Narcolepsy is a lifelong neurologic disorder characterized by excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep (DNS), sleep-related hallucinations, and sleep paral...

Gunjan Junnarkar , PhD;

Judith Profant , PhD, MS;

Jed Black , MD;

Teresa Steininger , PhD;

Roman Skowronski , MD, PhD;

10/08/2020

Examining Depressive Symptoms Across Diagnostic and Statistical Manual Indications: Treatment Effects of Brexpiprazole in Patients With Major Depressive Disorder and Schizophrenia

Background: The NIMH Research Domain Criteria (RDoC) framework could be used to recategorize symptoms across the established DSM criteria for neuropsychiatric disorder indications. This p...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Malaak Brubaker , PhD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Ruth Duffy , PhD;

10/08/2020

Depression in Parkinson`s Disease: Investigations of Pimavanserin, a Selective 5-HT2A Receptor Antagonist/Inverse Agonist

Depression occurs in 30–50% of Parkinson’s disease (PD) patients, yet no drugs are approved specifically to treat PD patients with depressive symptoms. Few clinical studies have been cond...

Rene Nunez , MD;

Maurizio Fava , MD, PhD;

Daryl DeKarske , MPH;

Lori Jacobi , BA;

Bruce Coate , MPH;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

10/08/2020

Evaluation of Treatment Failure in a Randomized, Open-Label Study of Paliperidone Palmitate Versus Oral Antipsychotics for Recent-Onset Schizophrenia or Schizophreniform Disorder

Background: Despite the availability of effective treatments, outcomes for patients with schizophrenia remain poor. Nonadherence is common early in the disease course, a time when the gre...

Amy O'Donnell , MD, JD, BS;

Ibrahim Turkoz , PhD;

Brianne Brown , PsyD;

Pamela Baker , PharmD;

Larry Alphs , MD, PhD;

10/08/2020

College Students Involved in Greek Life are at Higher Risk for Nonmedical Use of Prescription Stimulants, Particularly via Non-oral Routes

College students are an at-risk population for prescription stimulant nonmedical use (NMU; use for any reason or in any way other than prescribed, including misuse/abuse). An online surve...

Stephen Butler , PhD;

Stephen V. Faraone , PhD;

Jody Green , PhD;

10/08/2020

Demographic and Hospital Characteristics Influencing Length of Stay (LOS) in Bipolar Manic Inpatients receiving ECT

Objective: 1. to discern demographic predictors that may extend hospitalization length of stay (LOS) for bipolar disorder (BP) managed with electroconvulsive therapy (ECT), and 2. to stud...

Rikinkumar Patel , MD, MPH;

Krishna Priya Bodicherla , MBBS;

10/08/2020

Evaluation of Major Treatment Failures in Patients With Recent-Onset Schizophrenia: A Post Hoc Analysis From the Disease Recovery Evaluation and Modification (DREaM) Study

BACKGROUND: Major treatment failures (MTF), such as psychiatric hospitalization and arrest/incarceration, are associated with substantial economic and societal burden, especially for pers...

Amy O'Donnell , MD, JD, BS;

Ibrahim Turkoz , PhD;

Brianne Brown , PsyD;

Pamela Baker , PharmD;

Larry Alphs , MD, PhD;

10/08/2020

Disruption of Pharmacotherapy During the Transition From Adolescence to Early Adulthood in Patients With Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) treatment rates in adults are low, possibly owing to the discontinuation of care during the transition from adolescence to adulthood. To im...

William Spalding , MS;

Sepehr Farahbakhshian , MS;

Rajeev Ayyagari , PhD;

Daniel Barczak , MD;

Simerpal Gill , PhD;

Wenxi Tang , MS;

Thomas Kulalert , BA;

Madeline Jenkins , BS;

10/08/2020

This observational, noninterventional, prospective study described the person-centered experience of symptoms and impact of dementia-related psychosis (DRP) on patients from a patient and...

Victor Abler , DO;

Teresa Brandt , PhD;

Theresa Frangiosa , MBA;

Virginia Biggar , BA;

Angela Taylor , BA;

Bill Keller , MBA;

10/08/2020

Efficacy of Cariprazine in Patient Subgroups: Post Hoc Analysis of 3 Randomized, Placebo-Controlled Trials in Patients With Bipolar Depression

Introduction: Cariprazine is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat bipolar depression. The efficacy of cariprazine in patients wit...

Vladimir Maletic , MD;

Lakshmi Yatham , MBBS, FRCPC, MRCP, MBA;

Rakesh Jain , MD, MPH, RD;

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

10/08/2020

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products